Coave Therapeutics to Present at Upcoming Conferences

Coave Therapeutics to Present at Upcoming Conferences

Paris, France, September 28, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces that CEO Rodolphe Clerval will be presenting to investors and peers at the following Investor and Industry conferences:

• Chardan’s 7th Annual Genetic Medicines Conference – October 2-3

New York City, NY, USA

Presenting on October 2 at 11:30 EDT

• Cell & Gene Meeting on the Mesa – October 10-12

Carlsbad, CA, USA

Presenting on October 10 at 13:15 PDT and on panel “Science Slam: Path To Commercialization In Gene Therapy” at 14:00 PDT

• Jefferies London Healthcare Conference – November 14-15

London, UK

Attending and available for investor meetings

In addition, science and data from Coave’s pipeline programs will be presented at the following Scientific, Medical & Regulatory Conferences:

• EURETINA (European Society of Retina Specialists) Congress – October 5-8

Amsterdam, the Netherlands

Oral presentation by Professor G. Le Meur: “Design of a Phase 1/ 2 Trial to Study the Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients with Retinitis Pigmentosa (RP) Harbouring Mutations in the PDE6B (Phosphodiesterase 6B) Gene Leading to a Defect in PDE6B Expression.”

• RD 2023 – the XX^th International Symposium on Retinal Degeneration – October 23-28

Torremolinos, Spain

• ESGCT (European Society of Gene and Cell Therapy) 30^th Annual Congress – October 24-27

Brussels, Belgium

Oral Presentation by Dr. M.A. Burlot: “Intrastriatal injection of S0112AAV2-GBA1 is an efficient strategy to treat patients suffering from Parkinson’s disease related to GBA1 mutations.” Presentation on 27 October, 08:30-10:00 CEST (ID# OR65)

Poster presentation: “Improving AAV vectors via chemical engineering using the AAV-Ligand conjugation platform (ALIGATER™).” (Poster ID# P200)

Poster presentation: “Chemically modified AAV (coAAV) vectors from the AAV-Ligand Conjugate (ALIGATER™) platform possess modulated properties after systemic injection versus parental unconjugated capsids.” (Poster ID# P177)